share_log

Tonix Pharmaceuticals | DEF 14A: Definitive information statements

Tonix Pharmaceuticals | DEF 14A: Definitive information statements

Tonix Pharmaceuticals | DEF 14A：股東委託書決議
SEC announcement ·  04/16 04:40
牛牛AI助理已提取核心訊息
Tonix Pharmaceuticals Holding Corp. (Tonix) has announced its Annual Meeting of Shareholders to be held virtually on May 22, 2024. The meeting will address several key proposals, including the election of eight director nominees, the ratification of EisnerAmper LLP as the company's independent registered public accounting firm for the fiscal year ending December 31, 2024, and a reverse stock split proposal. The reverse stock split aims to authorize the Board of Directors to effect a reverse stock split of the company's common stock at a ratio not less than one-for-two and not greater than one-for-fifty, with the exact ratio to be determined by the Board within one year after stockholder approval. Additionally, the meeting will seek approval for the repricing of up to 94,398,656 shares of common stock issuable upon the exercise of warrants, in compliance with Nasdaq Listing Rule 5635(d). Shareholders of record as of March 25, 2024, are entitled to attend and vote at the meeting. Proxy materials will be furnished to shareholders on or about April 16, 2024.
Tonix Pharmaceuticals Holding Corp. (Tonix) has announced its Annual Meeting of Shareholders to be held virtually on May 22, 2024. The meeting will address several key proposals, including the election of eight director nominees, the ratification of EisnerAmper LLP as the company's independent registered public accounting firm for the fiscal year ending December 31, 2024, and a reverse stock split proposal. The reverse stock split aims to authorize the Board of Directors to effect a reverse stock split of the company's common stock at a ratio not less than one-for-two and not greater than one-for-fifty, with the exact ratio to be determined by the Board within one year after stockholder approval. Additionally, the meeting will seek approval for the repricing of up to 94,398,656 shares of common stock issuable upon the exercise of warrants, in compliance with Nasdaq Listing Rule 5635(d). Shareholders of record as of March 25, 2024, are entitled to attend and vote at the meeting. Proxy materials will be furnished to shareholders on or about April 16, 2024.
Tonix Pharmicals Holding Corp.（Tonix）宣佈其年度股東大會將於2024年5月22日虛擬舉行。會議將討論幾項關鍵提案，包括選舉八名董事候選人，批准EisnerAmper LLP作爲公司截至2024年12月31日的財政年度的獨立註冊會計師事務所，以及反向股票拆分提案。反向股票拆分旨在授權董事會以不低於一比二且不大於一比五的比例對公司的普通股進行反向分割，確切的比率將在股東批准後的一年內由董事會確定。此外，根據納斯達克上市規則5635（d），會議將尋求批准對行使認股權證時可發行的多達94,398,656股普通股進行重新定價。截至2024年3月25日的登記股東有權出席會議並在會上投票。代理材料將在2024年4月16日左右提供給股東。
Tonix Pharmicals Holding Corp.（Tonix）宣佈其年度股東大會將於2024年5月22日虛擬舉行。會議將討論幾項關鍵提案，包括選舉八名董事候選人，批准EisnerAmper LLP作爲公司截至2024年12月31日的財政年度的獨立註冊會計師事務所，以及反向股票拆分提案。反向股票拆分旨在授權董事會以不低於一比二且不大於一比五的比例對公司的普通股進行反向分割，確切的比率將在股東批准後的一年內由董事會確定。此外，根據納斯達克上市規則5635（d），會議將尋求批准對行使認股權證時可發行的多達94,398,656股普通股進行重新定價。截至2024年3月25日的登記股東有權出席會議並在會上投票。代理材料將在2024年4月16日左右提供給股東。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

譯文內容由第三人軟體翻譯。


牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生，只对除中国内地以外的地区提供。


以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。